Emergent BioSolutions Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2011 to Q1 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Emergent BioSolutions Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2011 to Q1 2022.
  • Emergent BioSolutions Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2022 was $1.9M.
  • Emergent BioSolutions Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$7.3M, a 78.3% increase from 2022.
  • Emergent BioSolutions Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$33.7M, a 178% decline from 2021.
  • Emergent BioSolutions Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $43M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2022 $1.9M +$3.6M Jan 1, 2022 Mar 31, 2022 10-Q 2022-04-29
Q1 2021 -$1.7M +$2.5M +59.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-29
Q1 2020 -$4.2M +$7.2M +63.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q1 2019 -$11.4M -$6.9M -153% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q1 2018 -$4.5M -$8.8M -205% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q1 2017 $4.3M +$1.34M +45% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-04
Q1 2016 $2.96M +$10.2M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-05
Q1 2015 -$7.26M +$791K +9.82% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-06
Q1 2014 -$8.05M -$3.54M -78.3% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q1 2013 -$4.52M -$11.5M -165% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q1 2012 $6.94M +$4.07M +141% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-03
Q1 2011 $2.88M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.